Skip to main content

BeyondSpring Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

BYSI$0.63-1.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

For the fiscal year ended December 31, 2025

Or

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ** to**

To

Commission File No. 001-38024

BeyondSpring Inc.

(Exact name of registrant as specified in its charter)

Cayman IslandsNot Applicable
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey07932
(Address of Principal Executive Offices)(Zip Code)

(646)305-6387

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per shareBYSIThe Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes☐ No ☒

As of June 30, 2025, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the Registrant’s ordinary shares held by non-affiliates of the Registrant was approximately $69.7 million, based upon the closing price of such shares on the Nasdaq Capital Market on June 30, 2025.

As of February 27, 2026,41,119,820 of the Registrant’s ordinary shares, par value $0.0001 per share, were outstanding.

FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2024

TABLE OF CONTENTS

Page

PART I.3
Item 1. Business3
Item 1.A. Risk Factors56
Item 1.B. Unresolved Staff Comments.120
Item 1C. Cybersecurity.120
Item 2. Properties.121
Item 3. Legal Proceedings.121
Item 4. Mine Safety Disclosures.121
PART II.122
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities122
Item 6. Selected Financial Data.129
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.129
Item 7.A. Quantitative and Qualitative Disclosure About Market Risk.140
Item 8. Financial Statements and Supplementary Data141
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.169
Item 9.A. Controls and Procedures.169
Item 9.B. Other Information.170
PART III.171
Item 10. Directors, Executive Officer and Corporate Governance.171
Item 11. Executive Compensation.175
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.183
Item 13. Certain Relationships and Related Transactions, and Director Independence.184
Item 14. Principal Accounting Fees and Services.186
PART IV.187
Item 15. Exhibits, Financial Statement Schedules.187

FORWARD-LOOKING STATEMENTS

This annual report on Form 10-K contains forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements stated in or implied by these forward-looking statements.

All statements other than statements of historical facts are forward-looking statements. These forward-looking statements are made under the “safe harbor” provision under Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and as defined in the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. You should refer to “Item 1A. Risk Factors” and elsewhere in this Annual Report on Form 10-K for specific risks that could cause actual results to be significantly different from those stated in or implied by these forward-looking statements. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from any future results stated in or implied by these forward-looking statements.

Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:

●the initiation, timing, progress and results of our studies in animals and clinical trials, and our research and development programs;
●our ability to advance our product candidates into, and successfully complete, clinical trials;
●our reliance on the success of our clinical-stage product candidates;
●the timing or likelihood of regulatory filings and approvals;
●our ability to address the concerns identified in the Complete Response Letter issued by the Food and Drug Administration, or FDA, in November 2021 regarding the New Drug Application, or NDA, seeking approval of Plinabulin in combination with granulocyte colony-stimulating factor, or G-CSF, for the prevention of chemotherapy-induced neutropenia, or CIN;
●our ability to file the NDA submission for the non-small cell lung cancer, or NSCLC indication with the National Medical Products Administration, or NMPA, in China;
●the commercialization of our product candidates, if approved;
●our ability to develop sales and marketing capabilities;
●the pricing and reimbursement of our product candidates, if approved;
●the implementation of our business model, strategic plans for our business and technology;
●the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
●our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;
●costs associated with defending intellectual property infringement, product liability and other claims;
●regulatory development in the United States, China and other jurisdictions;
●estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
●the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;
●our ability to maintain and establish collaborations or obtain additional grant funding;
●the rate and degree of market acceptance of our product candidates;
●developments relating to our competitors and our industry, including competing therapies;
●our ability to effectively manage our anticipated growth;
●our ability to attract and retain qualified employees and key personnel;
●our future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance;
●the future trading price of our ordinary shares and impact of securities analysts’ reports on these prices;
●our ability to meet Nasdaq’s continued listing requirements;
●the impact of widespread health developments, and the responses thereto, which could materially and adversely affect, among other things, enrollment of patients in our clinical trials, timing and completion of regulatory or other required inspections, our expected timeline for data readouts of our clinical trials and certain regulatory filings for our product candidates, and the review and approval timeline of regulatory authorities; and
●other risks and uncertainties, including those listed under “Item 1A. Risk Factors.”

The items in “Item 1A. Risk Factors” of this Annual Report on Form 10-K reference the principal contingencies and uncertainties to which we believe we are subject, which should be considered in evaluating any forward-looking statements contained in this Annual Report on Form 10-K.

The forward-looking statements in this Annual Report on Form 10-K speak only to our views as of the date of this Annual Report on Form 10-K and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.

This Annual Report on Form 10-K contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information included in this Annual Report on Form 10-K is generally reliable, such information is inherently imprecise.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.